Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis

Clicks: 372
ID: 267485
2021
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 19 articles by views in Journal of personalized medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aberrant methylation of tumor suppressor genes has been reported as an important epigenetic silencer in head and neck cancer (HNC) pathogenesis. Here, we performed a comprehensive meta-analysis to evaluate the overall and specific impact of salivary gene promoter methylation on HNC risk. The methodological quality was assessed using the Newcastle–Ottawa scale (NOS). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association and Egger’s and Begg’s tests were applied to detect publication bias. The frequency of salivary DNA promoter methylation was significantly higher in HNC patients than in healthy controls (OR: 8.34 (95% CI = 6.10–11.39; p < 0.01). The pooled ORs showed a significant association between specific tumor-related genes and HNC risk: p16 (3.75; 95% CI = 2.51–5.60), MGMT (5.72; 95% CI = 3.00–10.91), DAPK (5.34; 95% CI = 2.18–13.10), TIMP3 (3.42; 95% CI = 1.99–5.88), and RASSF1A (7.69; 95% CI = 3.88–15.23). Overall, our meta-analysis provides precise evidence on the association between salivary DNA promoter hypermethylation and HNC risk. Thus, detection of promoter DNA methylation in saliva is a potential biomarker for predicting HNC risk.
Reference Key
rapado-gonzález2021journalsalivary Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Óscar Rapado-González;Cristina Martínez-Reglero;Ángel Salgado-Barreira;María Arminda Santos;Rafael López-López;Ángel Díaz-Lagares;María Mercedes Suárez-Cunqueiro;Rapado-González, Óscar;Martínez-Reglero, Cristina;Salgado-Barreira, Ángel;Santos, María Arminda;López-López, Rafael;Díaz-Lagares, Ángel;Suárez-Cunqueiro, María Mercedes;
Journal Journal of personalized medicine
Year 2021
DOI
10.3390/jpm11070606
URL
https://www.mdpi.com/2075-4426/11/7/606/htm
Keywords
meta-analysis biomarkers dna methylation epigenetics head and neck cancer saliva liquid biopsy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.